Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
- Resource Type
- Article
- Authors
- Maillart, Elisabeth; Todesco, Eve; Assoumou, Lambert; Beigneux, Ysoline; Lubetzki, Catherine; Papeix, Caroline; De Paz, Raphael; Dubessy, Anne-Laure; Djebara, Siham; Louapre, Céline; Pourcher, Valérie
- Source
- Journal of Neurology. May2024, Vol. 271 Issue 5, p2871-2874. 4p.
- Subject
- *HEPATITIS B vaccines
*HIV seroconversion
*JOHN Cunningham virus
*HUMORAL immunity
*DISEASE risk factors
- Language
- ISSN
- 0340-5354
This document is a letter published in the Journal of Neurology discussing the humoral response to an accelerated schedule of hepatitis B virus (HBV) vaccination in patients with multiple sclerosis (MS) before receiving anti-CD20 therapy. The study was conducted in France and aimed to evaluate the efficacy and safety of the accelerated vaccination schedule. The results showed that 58.8% of MS patients achieved seroconversion after the first three injections of the vaccine, which is lower than the reported seroconversion rate for a standard vaccination schedule. The study also highlighted the need for long-term monitoring of immune responses and education on the risks of HBV transmission in MS patients. [Extracted from the article]